Tuberculosis (TB) is the commonest cause of death by a single infectious agent globally and
ranks amongst the top ten causes of global mortality. The incidence of TB is highest in Low …

Background Treatment of latent tuberculosis infection (LTBI) is effective in preventing
progression to TB disease. This study aimed to synthesize available evidence on the …

Background Dual neutralisation of interleukin 17A (IL17A) and interleukin 17F (IL17F) is a
potential novel therapeutic approach in psoriatic arthritis. We assessed bimekizumab, a …

About one fourth of the world's population is estimated to be infected with M. tuberculosis (1,
2). The risk of TB disease after infection depends on several factors, the most important …

• Most patients with TB disease should be initiated on a regimen of isoniazid, rifampin,
pyrazinamide and ethambutol until results of genotypic or phenotypic drug susceptibility are …

Latent tuberculosis infection (LTBI) management is now a critical component of the World
Health Organization's End TB Strategy. In this randomised controlled trial (Chinese Clinical …

Background Shorter regimens for tuberculosis prevention can improve completion rates and
protection against developing active tuberculosis disease after tuberculosis exposure. We …

Background Tuberculosis preventive treatment (TPT) is a key component of tuberculosis
elimination. To improve completion and reduce the burden for people and health systems …

Aims This study evaluated the neurodevelopmental toxicity of isoniazid (INH) in zebrafish
embryos and the underlying mechanism. Methods Zebrafish embryos were exposed to …

As Canada moves toward the elimination of tuberculosis (TB), the treatment of latent
tuberculosis infection (LTBI), referred to as tuberculosis preventive treatment (TPT), is …